博騰股份(300363.SZ):擬以2.66億元收購凱惠藥業100%股權
格隆匯3月9日丨博騰股份(300363.SZ)公佈,為匹配快速增長的臨牀前和臨牀早期(CRO)業務發展需求,公司擬以人民幣2.66億元的價格現金收購上海睿智化學研究有限公司(“睿智化學”)所持有的凱惠藥業(上海)有限公司(“凱惠藥業”、“標的公司”)100%股權。此次交易完成後,公司將持有凱惠藥業100%股權,凱惠藥業將成為公司全資子公司,並納入公司合併財務報表範圍。
此次交易完成後,凱惠藥業現有綜合實驗室、公斤級實驗室和中試車間,可為公司進一步擴大CRO業務提供產能保障;同時,凱惠藥業還將與公司上海研發中心形成聯動,有助於提升公司項目從研發到生產的切換效率,形成研產協同效應;另外,凱惠藥業作為國內較早從事小分子藥物研發及生產服務的企業之一,擁有良好的客户基礎和項目交付經驗,有利於公司進一步拓展國內業務,從而逐步推進公司端到端綜合製藥服務平台戰略的落地。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.